Current reports

Fulfilment of the condition precedent to the agreement with WPD Pharmaceuticals Sp. z o.o. for the provision of analytical method development services

Shareholder’s submission of a draft resolution on a matter included in the agenda of the Ordinary General Meeting of the Company convened for 26 May 2025

Receipt of a shareholder’s application to extend the agenda of the Ordinary General Meeting to include an item on changes to the Incentive Scheme

Annual Report – information on corrections to appendices

Announcement on convening the Ordinary General Meeting of Mabion S.A. for 26 May 2025, together with draft resolutions

Mabion S.A. adopts its Strategy for 2025–2030 and updates its ESG Strategy for 2025–2027

Strategy for 2025–2030

Mabion enters into an agreement with WPD Pharmaceuticals sp. z o.o. for the provision of analytical method development services

Mabion enters into a strategic cooperation agreement with Sartorius Stedim Cellca GmbH to jointly commercialise services

Mabion enters into a master agreement and places an order with Instituto de Biologia Molecular do Paraná (IBMP); disclosure of delayed confidential information

Change of publication dates of the Company’s interim reporting

Deadlines for publication of periodic reports in the financial year 2025

Conclusion of an annex to the agreement for the manufacture and delivery of a leakage control and optical inspection line for direct packaging

Decision to abandon the intention to enter into a co-financing agreement for a project as part of the FENG call – SMART Path

Registration of a conditional increase in share capital and an amendment to the Articles of Association

Change of the publication date of the Q3 2024 report

Mabion enters into a master agreement with a UK client

Change in the composition of the Company’s Management Board

Information on the activities undertaken to enter into a project agreement as part of the FENG call – SMART Path

Winning orders from a new UK client

List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company after the meeting resumed on 15 July 2024

List of shareholders holding at least 5%

Contents of resolutions put to the vote at the Ordinary General Meeting of Mabion S.A. after the meeting resumed on 15 July 2024

Extension of cooperation with Novavax, Inc. and conclusion of an annex to the quality agreement

List of shareholders holding at least 5% of votes at the Company’s Annual General Meeting on June 17, 2024 until the adjournment of the meeting

List of shareholders holding at least 5%

Changes to the composition of the Supervisory Board

Adjournment of the Ordinary General Meeting of Mabion S.A. and content of resolutions adopted until the adjournment

Resignation of a member of the Company’s Supervisory Board

Mabion receives as a notice of candidacies for Members of the Company’s Supervisory Board

Resignation of a member of the Company’s Supervisory Board

Notice convening the Annual General Meeting of Mabion S.A. for 17 June 2024, together with draft resolutions

Estimated financial results of the Company for 2023 and information on the write-down of fixed assets under construction

Deadlines for publication of periodic reports in the financial year 2024

Changes in the composition of the Management Board

Update on the scope of services provided to Novavax, Inc. under SOW#8.

Mabion enters into an agreement for the manufacture and delivery of a direct packaging leakage check and optical inspection line to the Company’s manufacturing facility

Registration of amendments to the Company’s Articles of Association

Information update on the loan agreement with the European Bank for Reconstruction and Development

Conclusion of an agreement for the supply of bioreactor set to the Company’s manufacturing facility

List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company after the meeting resumed on 13 June 2023.

List of shareholders holding at least 5% of the number of votes at the Ordinary General Meeting of Mabion S.A. on 7 June 2023 until the adjournment

Contents of resolutions put to the vote at the Ordinary General Meeting of Mabion S.A. after the meeting resumed on 13 June 2023

Contents of the resolutions put to the vote at the general meeting of Mabion S.A. held on 13 June 2023

List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company on 7 June 2023 until the adjournment

List of shareholders holding at least 5% of the number of votes at the Ordinary General Meeting of Mabion S.A. on 7 June 2023 until the adjournment

Appointment of Members of the Supervisory Board for the 3rd joint term of office

David John James – biogram

Józef Banach – biogram

Robert Koński – biogram

Sławomir Kościak – biogram

Wojciech Wośko – biogram

Zofia Szewczuk – biogram

Adjournment of the Ordinary General Meeting of Mabion S.A. and content of resolutions adopted until the adjournment

Contents of the resolutions of ordinary general meeting of Mabion S.A. of 7 June 2023

Remuneration policy for members of the management board and supervisory board of Mabion S.A. with its registered office in Konstantynów Łódzki

Submission of nominations for Members of the Supervisory Board

Robert Koński – biogram

Józef Banach – biogram

Zofia Szewczuk – biogram

Sławomir Kościak – biogram

David John James – biogram

Mabion receives as a notice of candidacy for a Member of the Company’s Supervisory Board

Conclusion of an annex to the agreement for the supply of bioreactors to the Company’s manufacturing facility

The Company terminates its agreement with Parexel for the clinical trial of MabionCD20

Notice convening the Annual General Meeting of Mabion S.A. for 7 June 2023, together with draft resolutions

Decision to close the patent procedures for MabionMS

Mabion S.A. adopts the Company Strategy for 2023–2027 and discloses delayed confidential information on the adoption of the strategy’s initial framework assumptions

Company Strategy for 2023–2027

Change of publication date of the annual report for 2022

Mabion signs annex with Novavax, Inc. for the manufacture of COVID-19 vaccine antigen, Omicron variant

Extension of cooperation with Novavax, Inc.

Termination of non-binding agreement with Polski Fundusz Rozwoju S.A.

Mabion signs a loan agreement for USD 15,000,000 with the European Bank for Reconstruction and Development

Deadlines for publication of periodic reports in the financial year 2023

KDPW’s statement on the assimilation of the Company’s S series ordinary bearer shares

Admission and introduction of the Company’s S series ordinary bearer shares to stock exchange trading

Extension of cooperation with Novavax, Inc.

The Company terminates the co-financing agreement for the project “Expansion of the Research and Development Centre of Mabion S.A. – research on a new generation of medicines”

Credit Committee of the European Bank for Reconstruction and Development approves financing for the Company

Broadening and extension of cooperation with Novavax, Inc. – Omicron variant

Change of the publication date of the first half of 2022 report

Allotment of shares and increase of the Company’s share capital as part of a conditional share capital increase

Statement of the Central Securities Depository of Poland on the registration of the Company’s S series shares

Summary of the subscription of the Company’s S series ordinary bearer shares carried out as part of the Incentive Scheme for 2021

Extension of cooperation with Novavax, Inc.

Extension of cooperation with Novavax

Registration of amendments to the Company’s Articles of Association.

Attachment

Receipt a notification of a change in the Company’s shareholding

Attachment

Conclusion of an annex to the loan agreement with Glatton Sp. z o.o.

Extension of cooperation with Novavax, Inc.

List of shareholders holding at least 5% of the votes at the Annual General Meeting of the Company on 21 June 2022.

Attachment

Contents of the resolutions of the Annual General Meeting of Mabion S.A. of 21 June 2022.

Attachment no. 1

Attachment no. 2

Extension of cooperation with Novavax

Extension of the scope of services under of manufacturing agreement with Novavax

Appointment of Members of the Management Board of Mabion S.A. for the second joint term of office

Notice of convening the Ordinary General Meeting of Mabion S.A. for 21 June 2022, together with draft resolutions

Change of dates of publication of interim reports in financil year 2022

KDPW’s statement on the assimilation of S series ordinary bearer shares of the Company

Admission and introduction of S series ordinary bearer shares of the Company to stock exchange trading

Registration of the Company as the manufacturer of the SARS-CoV-2 rS active substance in the Register of the Chief Pharmaceutical Inspectorate

Conclusion of an annex to the agreement on co-financing of the project entitled “Expansion of the Research and Development Centre of Mabion S.A. – research on the new generation of medicines”

Change of the publication date of the annual report for 2021

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities

Decision to abandon further implementation of the research project on the development of MabionEGFR

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.

Allotment of shares and increase of the Company’s share capital as part of a conditional share capital increase

Announcement of the National Depository of Securities (Krajowy Depozyt Papierów Wartościowych S.A.) concerning the registration of S series shares of the Company.

Mabion receives an additional order to provide analytical product quality control services under manufacturing agreement with Novavax, Inc.

Mabion receives an additional order for the production of cellular banks under the manufacturing agreement with Novavax, Inc.

Deadlines for publication of periodic reports in the financial year 2022.

Notification of transactionson Mabion S.A.’s shares performed by a person discharging managerial responsibilities.

Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with reumatoid arthritis in Ukraine.

Subscription summary for the Company’s S series ordinary bearer shares as part of the Incentive Scheme for 2020.

An addendum to Current Report no. 26/2021 containing information on the completed subscription of U series shares issued by Mabion S.A.

Mabion executes an annex to the borrowing agreement with Glatton Sp. z o.o.

Resignation of a member of the Company’s Supervisory Board.

Mabion enters into an agreement for the supply of four bioreactors to the Company’s manufacturing facility.

Mabion enters into a quality agreement as part of its collaboration with Novavax, Inc.

Termination of the cooperation agreement with Mylan Ireland Ltd.

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Belgium.

Change of the publication date of the Q3 2021 report.

Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.

Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Georgia.

Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Poland.

Information on the execution of a commercial manufacturing agreement with Novavax, Inc. for the period of 2022-2025

Registration of amendments to the Company’s Articles of Association.

Change of the permit for business activity in the Łódź Special Economic Zone.

Adoption of a joint work programme for the marketing authorisation of MabionCD20 in the European and US markets and elaboration of the final data and clinical trial scope for the registration application on the European market.

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.

Receipt of the notice of the company’s shareholding

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial resposibilities.

Update on the cooperation with Novavax Inc. on the COVID-19 vaccine programme.

List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 22, 2021

Appointment of a Member of the Company’s Supervisory Board. Appointment of a Member of the Company’s Supervisory Board

The content of the resolutions of the Ordinary General Meeting of Mabion S.A. of 22 June 2021

Receipt of the notice of change in the company’s shareholding.

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.

Receipt of a motion to supplement the agenda of the General Meeting and a candidacy for Member of the Supervisory Board

Announcement on convening the Ordinary General Meeting of Mabion S.A. on June 22, 2021, alongside with draft resolutions

Changes in the composition of the Company’s Management Board and Supervisory Board – correction of the numbering of the Current Report of 13 May 2021.

Changes in the composition of the Company’s Management Board and Supervisory Board.

Conclusion of an annex to the cooperation agreement with Mylan Ireland Ltd.

Admission and introduction of ordinary bearer series U shares of the Company to stock exchange trading

The conditional registration of series U shares of the Company with the National Depository for Securities

Change of the publication date of the annual report for 2020

Registration of the share capital increase and amendments to the Articles of Association

Information on the performance of the first order under a framework agreement with Novavax, Inc.

Registration of rights to series U shares of the Company in KDPW

Admission and introduction of the rights to ordinary bearerseries U shares of the Company to exchange trading

Conditional registration of rights to series U shares of theCompany in KDPW

Information regarding the completed subscription for series Ushares issued by Mabion S.A.

Cancellation of the Extraordinary General Meeting of MabionS.A. called for 22nd March 2021 and information on the review of the Company’s financing strategy

Notifications about transactions on Mabion S.A. shares made by persons closely related to persons discharging managerial responsibilities in the Company

Conclusion of contracts for the subscription for series U Mabion S.A. shares

Notification of transactions on Mabion S.A. shares performed bythe person discharging managerial responsibilities

Determination of the issue price of new Series U shares issued by MabionS.A. and the final number of series U shares to be offered by the Company

Information on declarations of particular shareholderssubmitted in connection with the book-building process

Mabion S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription ofnew Series U ordinary bearer shares issued by Mabion S.A.

Changes in the composition of the Management Board and Supervisory Board of the Company

Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities

Conclusion of a preliminary agreement with Polski Fundusz Rozwoju S.A.

Entering into a master service agreement with the first work order with Novavax Inc. for contract services related to the COVID-19 vaccine program

List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on February 23, 2021

Changes in the composition of the Supervisory Board of the Company

Content of resolutions of the Extraordinary General Meeting of Mabion S.A. of 23 February 2021

Announcement on the convening of the Extraordinary General Meeting of Mabion S.A. of March 22, 2021 together with draft resolutions

Issue of shares as part of the conditional increase of the Company’s share capital

Registration of S series shares in KDPW

Admission and introduction of S series shares to exchange trading

Resignation of a Member of the Supervisory Board of the Company

Receipt of nomination for member of the Supervisory Board of the Company

Conclusion of a loan agreement with Twiti Investments Limited

Announcement on convening the Extraordinary General Meeting ofMabion S.A. on February 23, 2021, alongside with draft resolutions

Decision on commencing activities aimed at attracting astrategic investor for the Company and on two planned issues of the Company’s shares

Assignment of Supervisory Board member to perform the duties of a member of the Management Board

Dates for submission of periodical reports in the financial year of 2021

Statement of the National Depository for Securities S.A. concerning: the conditional registration of series S shares with the National Depository for Securities

The fifth summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office

Conclusion of an annex to the loan agreement with Glatton Sp. z o.o.

Update of information regarding the Company’s cooperation with Vaxine Pty Ltd. regarding a potential Covid-19 vaccine

The fourth summons to shareholders of Mabion S.A. forsubmitting the share documents in the Company’s registered office

The third summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office

Updated information concerning the Company’s cooperation with Vaxine Pty Ltd. in scope of a potential Covid-19 vaccine

Conclusion of an agreement with Parexel to conduct the final clinical trial before submitting a marketing authorisation application for MabionCD20 to the European Medicines Agency (EMA)

Signing of the initial understanding in scope of cooperation covering research, development, and commercialisation of the antibodies of drug MabionCD20 in specific clinical indications concerning rare diseases.

Receipt of a notification of change in the ownership of the Company’s shares

The second summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office

Signing of a Letter of Intent (LoI) on development work and production of the “IL-1R7 Antibody”, developed as a possible medication to treat Covid-19 infections.

The first summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office

Assignment of Supervisory Board member to replace a member of the Management Board

Conclusion of Memorandum of Understanding on potential cooperation regarding a product that may be a vaccine for Covid-19 disease

Resignation of a Member of the Management Board of the Company.

Information regarding a meeting with the US Food and Drug Administration (FDA) concerning registration and marketing authorization for MabionCD20 drug on the territory of the USA.

Conclusion of loan agreements from the main Shareholders of the Company

Conclusion of loan agreement with Glatton Sp. z o. o.

Information on initial assumptions regarding the renewed Marketing Authorization Application to be filed for MabionCD20

Receipt of a written response from the European Medicines Agency as a part of the ‘Scientific Advice’ regarding the assumptions for the new registration process for MabionCD20

Summary of the subscription of S series ordinary bearer shares of the Company carried out under the Incentive Scheme for 2019

Satisfaction of the condition of the permit to conduct business activity in the Łódź Special Economic Zone.

List of shareholders holding at least 5% of votes at the Ordinary General Meetingof the Company on June 15, 2020.

Appointment of Supervisory Board members for the second term

Attachment

Content of the resolutions of the Ordinary General Meeting of Mabion S.A. of June 15, 2020

Announcement on convening the Ordinary General Meeting of Mabion S.A. on June 15, 2020, along with draft resolutions

Decision on the intention to issue U series ordinary bearer shares of the Company in order to increasethe share capital of Mabion S.A.

Change of publication date of the annual report for 2019

Information on the withdrawal of registration applications for MabionCD20 from the EMA

Changes in the positions of Chairman and Deputy Chairman of the Supervisory Board

Information on the impact of the COVID-19 spread on the Company’s activities

Arrangements for financing the Company’s operations in light of the new regulatory strategy for registration of MabionCD20 in the EMA

Change of regulatory strategy for the marketing authorisation of MabionCD20 in the EMA

Resignation of a Member of the Supervisory Board of the Company and appointment of President of the Management Board of the Company

Update on the registration procedure for the marketing authorisation of MabionCD20 by the European Medicines Agency

Receipt of a summary of a BPD Type 3 meeting with the Food and Drug Administration (FDA) on the registration and marketing authorisation of MabionCD20 in the USA

Receipt of the list of issues to be presented at the meeting of the Committee for Medicinal Products for Human Use to be held on 24-27 February 2020

Change of the building permit for Mabion S.A. Science and Technology Centre for Advanced Medical Biotechnology in Konstantynów Łódzki.

Change of the authorisation to conduct business activity in the Łódź Special Economic Zone

Issue of shares under a conditional increase of the Company’s share capital

Submitting answers to the questions as part of the registration procedure for MabionCD20 with the European Medicines Agency

Registration of P and S series shares in KDPW

Admission and introduction of P and S series shares to exchange trading

Information regarding a Type 3 BPD meeting with the Food and Drug Administration (FDA) on the registration and marketing authorisation of MabionCD20 in the USA

Declaration of the National Depository for Securities (KDPW) on conditional registration of P and S series shares in the KDPW

Update information on the registration procedure for MabionCD20.

Dates of publication of periodic reports in the financial year 2020.

Receipt of the summary from the CHMP meeting regarding the registration procedure of the MabionCD20 drug.

Update of information concerning the registration of drug MabionCD20 for marketing authorisation and disclosure of delayed confidential information.

Obtaining approval on extension of the research project deadline from the National Centre for Research and Development.

Registration of conditional increase of share capital and amendment to the Articles os Association.

List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on November 29, 2019.

Summary of the subscription of the Company’s ordinary series S bearer shares carried out as part of the implementation of the Incentive Program for 2018.

Contents of resolutions adopted by the Extraordinary Meeting of Shareholders of Mabion S.A. on 29 November 2019.

Notifications about transactions on Mabion S.A. financial instruments made by a person discharging managerial responsibilities.

Submission of answers to the Company’s Duplicate application for registration of MabionCD20 with the European Medicines Agency.

Responses to round two of inquiries in scope of the registration procedure of MabionCD20 in the European Medicines Agency.

Notice of convening the Extraordinary General Meeting of Mabion S.A. to be held on November 29, 2019, with draft resolutions attached.

Appointment of BPD Type 3 meeting with the US Food and Drug Administration_FDA_concerning registration and marketing authorisation for the drug MabionCD20 within the territory of the United States.

Agreement reached on the terms and conditions of and a decision made to conclude finance documentation with the European Investment Bank.

Obtaining the GMP certificate for the Complex in Konstantynow Lodzki in the field of manufacturing a medicinal product.

nformation on cooperation with Mylan.

Registration of amendment to the Company’s Statute.

Information from the European Medicines Agency on the assessment of the results of GMP inspection related to MabionCD20 production in the complex in Konstantynów Łódzki.

Mabion S.A. obtains the GMP certificate for the complex in Konstantynów Łódzki for the production of the production of the active substance.

Receipt of the second round of questions in the MabionCD20 registration procedure at the European Medicines Agency.

Update of information on the composition of the Management Board of the Company.

List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 18, 2019. – correction

List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 18, 2019.

Content of the resolutions of the Ordinary General Meeting of Mabion S.A. of June 18, 2019.

Implementation of the last condition of permission for conducting the operation in the Lodz Special Economic Zone at the Scientific and Industrial Complex of Medical Biotechnology in Konstantynow Lodzki.

The acceptance of the second registration application for MabionCD20 drug for assessment by the European Medicines Agency.

Notice of convening the Ordinary General Meeting of Mabion S.A. to be held on June 18, 2019, with draft resolutions attached.

The submission of the second registration application concerning MabionCD20 drug to the European Medicines Agency.

Receipt of the notice of a change in ownership of the Company’s shares

Resignation from the function of President of the Company’s Management Board.

Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency – report correction.

Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency.

Change in the date of publication of the annual report for 2018.

The update on development strategy of medicinal products.

Conversion of ordinary registered series P shares into ordinary bearer shares.

Information on the registration procedure for MabionCD20 in Turkey.

Fulfilment of the condition stipulated in the permit for conducting economic activity in the area of the Lodz Special Economic Zone at the Medical and Biotechnology Complex in Konstantynow Lodzki.

Notification about transactions on Mabion S.A. shares made by a person closely associated with a person fulfilling managing responsibilities

Notification about transactions on Mabion S.A. shares made by a person closely associated with a person fulfilling managing responsibilities

Dates of publication of periodic reports in the financial year 2019.

Notifications about transactions on Mabion S.A. performed by person fulfilling managing responsibilities.

Change in the Company’s Management Board.

Notifications about transactions on Mabion S.A.

Filing an application for an extension of patent protection in PCT procedure as part of the MabionMS project.

Receiving a building permit for ”The Scientific and Technological Center of Advanced Medical Biotechnology Mabion S.A” in Konstantynów Łódzki.

Submission of the second patent application under the MabionMS project.

Receipt of payments for the implementation of the key stage of the cooperation agreement with Mylan Ireland.

Receipt of the notification of the change in the number of Company’s shares.

Granting of approval from The European Medicines Agency for submitting the second registration application (‘Duplicate application) for the drug under the working name MabionCD20.

Signing a revolving credit agreement with BZ WBK S.A.

Ordinary General Meeting of Shareholders on 28th June 2018 – list of shareholders with at least 5% of the votes.

Appointment of Members of the Supervisory Board.

The content of the resolution of the Ordinary General Meeting of Shareholders of Mabion S.A. on 28th June 2018.

Resignation of the Member of the Supervisory Board of the Company.

Information regarding a meeting with the US Food and Drug Administration _FDA_ concerning registration and marketing authorization for MabionCD20 drug on the territory of the USA.

Resignation of the Member of the Supervisory Board of the Company.

Announcement of candidacy for the Member of the Supervisory Board of the Company.

Resignation of the Chairman of the Supervisory Board of the Company.

Acceptance for evaluation of marketing authorization application for MabionCD20 drug by the European Medicines Agency.

The submission by the shareholder drafts of resolutions for the Ordinary General Meeting of Mabion S.A. convened on 28th

Announcement of candidacy for the Member of the Supervisory Board of the Company.

Registration of class P shares in KDWP.

Admission and introduction of P class shares to stock exchange trading.

Announcement of candidacy for the independent Member of the Supervisory Board of the Company.

Announcement of candidacy for the independent Member of the Supervisory Board of the Company

Statement of Krajowy Depozyt Papierów Wartościowych S.A. on conditional registration of shares.

Announcement of candidacy for the independent Member of the Supervisory Board of the Company

The Reports of Mabion S.A. Management Board submitted to Ordinary General Meeting convened on 28th June, 2018.

The announcement on summoning the Ordinary General Meeting of Mabion S.A. on 28th June, 2018, along with draft resolutions.

The application for approval of MabionCD20 to the European Medicines Agency.

Confirmation of the final results of the Mabion CD20 NHL clinical trial.

The change of ordinary series P bearer shares into ordinary nominative shares.

Receipt of the notification of the change in the number of Company’s shares.

Change of publication date of the report for the first quarter of 2018.

Receipt of the notification of the change in the number of Company’s shares.

Receipt of the notification of the change in the number of Company’s shares.

Receipt of the notification of the change in the number of Company’s shares.

The registration of the share capital increase through the issue of series P shares and repealing the records of the Statute concerning the authorized capital-adjustment.

The registration of the share capital increase through the issue of series P shares and repealing the records of the statute concerning the authorized capital.

Notification of transactions on Mabion S.A. shares done by a person closely related to a peson discharging managerial responsibilites.

Execution of the argeement on subscription of P shares with Twiti Investements Ltd.

List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company.

Changes of the Articles of Association of Mabion S.A. by the Extraordinary General Meeting on 18 April 2018.

Resolutions adopted by the Extraordinary General Meeting of the Company on 18 April 2018.

Expansion of Mabion S.A.’s Research and Development Centre selected for co-funding.

Receipt of notification of a change in the status of ownership of the Company’s shares.

Receipt of the notification of the status of ownership of the Company’s shares.

Receipt of notification of a change in the status of ownership of the Company’s shares.

Change of the publication date of the annual report for 2017.

Notification of transactions in shares of Mabion S.A. Carried out by a person discharging managerial responsibilities.

Planned amendments to the Company’s Articles of Association.

Convocation of the Extraordinary General Meeting of Mabion S.A. for 18 April 2018 with draft resolutions.

Execution of agreements related to funding obtained by Mabion S.A. (correction).

Confirmation of the final results of the Mabion CD20 RZS clinical trial.

Execution of agreements related to funding obtained by Mabion S.A.

Registration of N and O shares in the Central Securities Depository.

Admission and introduction of N and O shares to stock exchange trading.

Conditional registration of N and O shares in the Central Securities Despository.

Notification of transactions in shares of Mabion S.A. carried out by a person discharging managerial responsibilities.

Notification of transactions in shares of Mabion S.A. carried out by a person discharging managerial responsiblities.

Results of the clinical trial related to MabionCD20 NHL in relation to other pharmacokinetic endpoints.

Notification of transactions in shares of Mabion S.A. carried out by a person discharging managerial responsibilities.

Information on the last visit of the last patient in the MabionCD20 NHL trial and conclusion of long-term observation.

Results of the clinical trial related to MabionCD20 NHL in relation to certain secondary phamacokinetic endpoints (treatment efficacy and general safety profile).

Positive initial results of the clinial trial related to Mabion CD20 NHL in reletion to the primary pharmacokinetic secondary endpoints.

Dates of publication of interim reports in the financial year 2018.